The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
Open accessPublished version of a preprint
Abstract
UNLABELLED: Despite the unprecedented clinical activity of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib in mantle cell lymphoma (MCL), acquired resistance is common. By longitudinal integrative whole-exome and whole-transcriptome sequencing and targeted sequencing, we identified the first relapse-specific C481S mutation at the ibrutinib binding site of BTK in MCL cells at progression following a durable response. This mutation enhanced BTK and AKT activation and tissue-specific proliferation of resistant MCL cells driven by CDK4 activation. It was absent, however, in patients with primary resistance or progression following transient response to ibrutinib, suggesting alternative mechanisms of resistance. Through synergistic induction of PIK3IP1 and inhibition of PI3K-AKT activation, prolonged early G1 arrest induced by PD 0332991 (palbociclib) inhibition of CDK4 sensitized resistant lymphoma cells to ibrutinib killing when BTK was unmutated, and to PI3K inhibitors independent of C481S mutation. These data identify a genomic basis for acquired ibrutinib resistance in MCL and suggest a strategy to override both primary and acquired ibrutinib resistance. SIGNIFICANCE: We have discovered the first relapse-specific BTK mutation in patients with MCL with acquired resistance, but not primary resistance, to ibrutinib, and demonstrated a rationale for targeting the proliferative resistant MCL cells by inhibiting CDK4 and the cell cycle in combination with ibrutinib in the presence of BTK(WT) or a PI3K inhibitor independent of BTK mutation. As drug resistance remains a major challenge and CDK4 and PI3K are dysregulated at a high frequency in human cancers, targeting CDK4 in genome-based combination therapy represents a novel approach to lymphoma and cancer therapy. Cancer Discov; 4(9); 1022-35. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 973.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar mechanistic considerations may underlie synergism of CDK4/6 inhibition with ibrutinib-mediated BTK inhibition; additionally, combined CDK4/6-PI3Kδ Inhibition may also be an effective strategy following the development of acquired ibrutinib resistance (124).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citationHonigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Self-citationBRUTON, O. C. (1952) · Pediatrics · doi:10.1542/peds.9.6.722 · Cited by 1,492
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275 · cited 5×
“No gainof-function R665W mutation in the downstream PLCγ2 observed in ibrutinib relapse in CLL (23) was detected (Supplementary Table S5).”
BackgroundInfluentialSelf-citationFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 741
Lannutti, B. J., Meadows, S. A., Herman, S. E. M., Kashishian, A., Steiner, B., Johnson, A. J., Byrd, J. C., Tyner, J. W., Loriaux, M. M., Deininger, M., et al. (2011) · Blood · doi:10.1182/blood-2010-03-275305 · Cited by 720
Self-citationPI3 Kinase Signals BCR-Dependent Mature B Cell Survival
Srinivasan, L., Sasaki, Y., Calado, D. P., Zhang, B., Paik, J. H., DePinho, R. A., Kutok, J. L., Kearney, J. F., Otipoby, K. L., & Rajewsky, K. (2009) · Cell · doi:10.1016/j.cell.2009.08.041 · Cited by 661
Hoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H., Keating, M. J., Giese, N., O'Brien, S., Yu, A., Miller, L. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352492 · Cited by 549
Cited by
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8545 · Cited by 484
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Mato, A. R., Shah, N. N., Jurczak, W., Cheah, C. Y., Pagel, J. M., Woyach, J. A., Fakhri, B., Eyre, T. A., Lamanna, N., Patel, M. R., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00224-5 · Cited by 466
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Burger, J. A., & Wiestner, A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.121 · Cited by 431
Metadata
- Authors
- Chiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., Johnson, A., Chang, B., Ely, S., Elemento, O., Mason, C. E., Leonard, J. P., & Chen-Kiang, S.
- Affiliations
- Weill Cornell Medicine (US)
- 1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York.
- Willamette Valley Cancer Institute and Research Center (US)
- Cornell University (US)
- Foundation Medicine (United States) (US)
- The Ohio State University (US)
- Pharmacyclics (United States) (US)
- ORCID
- Venue
- Cancer Discovery
- Published
- 2014-09-01
- Volume
- 4
- Issue
- 9
- Pages
- 1022-1035
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4155003
- OpenAlex
- W2028681024
- Cited by
- 273
- References
- 39
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 18 · 2023: 13 · 2022: 13 · 2021: 27 · 2020: 32 · 2019: 31 · 2018: 33 · 2017: 30 · 2016: 38 · 2015: 23
- FWCI
- 22.56
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-11-01)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- National Institutes of Health (5t32gm083937-09)
- Weill Cornell Medical College
- National Cancer Institute (R21CA176362)
- National Institute of General Medical Sciences (T32-GM083937)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- mantle cell lymphoma, ibrutinib resistance, BTK C481S mutation, acquired drug resistance, PI3K inhibition, CDK4 inhibition, palbociclib, PIK3IP1, cell cycle reprogramming, G1 cell cycle arrest, combination therapy, Akt activation, relapse
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Phosphoinositide-3 Kinase Inhibitors, Adenine, Antineoplastic Agents, Cell Cycle, DNA Mutational Analysis, Drug Synergism, Enzyme Activation, Humans, Mutation, Neoplasm Recurrence, Local, Nitrates, Piperidines, Polyethylene Glycols, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Signal Transduction, NF-kappa B, Treatment Outcome, Drug Resistance, Neoplasm, Amino Acid Substitution, Lymphoma, Mantle-Cell, Genomics, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Proto-Oncogene Proteins c-bcr
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-14-0098
- The paper
- Chiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., Johnson, A., Chang, B., Ely, S., Elemento, O., Mason, C. E., Leonard, J. P., & Chen-Kiang, S. (2014). Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-14-0098
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.